August 2023

BenevolentAI doses participants in BEN-8744 study

The candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis BenevolentAI, a company focusing on artificial intelligence (AI) that boosts biopharma discovery, has revealed that the initial group of participants have been dosed across a phase 1 clinical trial of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744. Currently in

BenevolentAI doses participants in BEN-8744 study Read More »

Scroll to Top